Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

2.530 +0.050 (+2.02%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Price and Volume

Volume	30,164
Open	2.607
Bid (Size)	2.500 (100)
Ask (Size)	2.540 (900)
Prev. Close	2.480
Today's Range	2.475 - 2.607
52wk Range	2.200 - 6.520
Shares Outstanding	3,192,040
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Today 8:05 EDT

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

July 15, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	-27.1%	-27.1%
1 Month	-2.7%	-2.7%
3 Month	-1.2%	-1.2%
6 Month	-23.6%	-23.6%
1 Year	-46.3%	-46.3%

More News

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

June 01, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar (CLRB) Q1 2026 Earnings Transcript ↗

May 14, 2026

Via The Motley Fool

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 14, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

May 11, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

May 05, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

May 05, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

April 21, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

April 14, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

Via The Motley Fool

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

March 04, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

February 25, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Expands Global Intellectual Property Estate

February 17, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

January 09, 2026

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

December 16, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Earnings Outlook For Cellectar Biosciences ↗

November 12, 2025

Via Benzinga

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

November 06, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

October 27, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

October 14, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 07, 2025

Via Benzinga

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗

October 07, 2025

Via Stocktwits

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

October 07, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?

Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?

Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?

The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market

What is the current price of Cellectar Biosciences, Inc. - Common Stock?

The current price of Cellectar Biosciences, Inc. - Common Stock is 2.530

When was Cellectar Biosciences, Inc. - Common Stock last traded?

The last trade of Cellectar Biosciences, Inc. - Common Stock was at 07/30/26 04:00 PM ET

What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?

The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 8.08M

How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?

Cellectar Biosciences, Inc. - Common Stock has 8M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.